Pituitary Apoplexy Following Gonadotropin-Releasing Hormone Agonist Administration for Prostate Cancer.
1/5 보강
[INTRODUCTION] Pituitary apoplexy represents an uncommon endocrine emergency with potentially life-threatening consequences.
APA
Fujimura M, Shimizu T, et al. (2026). Pituitary Apoplexy Following Gonadotropin-Releasing Hormone Agonist Administration for Prostate Cancer.. IJU case reports, 9(2), e70159. https://doi.org/10.1002/iju5.70159
MLA
Fujimura M, et al.. "Pituitary Apoplexy Following Gonadotropin-Releasing Hormone Agonist Administration for Prostate Cancer.." IJU case reports, vol. 9, no. 2, 2026, pp. e70159.
PMID
41767037 ↗
Abstract 한글 요약
[INTRODUCTION] Pituitary apoplexy represents an uncommon endocrine emergency with potentially life-threatening consequences. Gonadotropin-releasing hormone agonist used for prostate cancer has the potential to induce pituitary apoplexy, particularly in the setting of a preexisting pituitary adenoma.
[CASE PRESENTATION] A 76-year-old male with prostate cancer initially chose active surveillance; however, prostate-specific antigen (PSA) elevation required hormonal therapy 5 years later. A pancreatic islet tumor had been previously identified; however, its details were unavailable. He was presented to the emergency department 24 h after receiving the first gonadotropin-releasing hormone agonist injection. He showed severe headache, general fatigue, diplopia, and ptosis of the right eye. Brain MRI revealed a right deviated suprasellar pituitary adenoma with hemorrhagic infarction. He was conservatively treated with high-dose steroids; symptoms improved within 1 week.
[CONCLUSION] Clinicians should be aware of the association of pituitary apoplexy with the use of gonadotropin-releasing hormone agonist and should ask about the patient's past history of multiple endocrine neoplasia (MEN).
[CASE PRESENTATION] A 76-year-old male with prostate cancer initially chose active surveillance; however, prostate-specific antigen (PSA) elevation required hormonal therapy 5 years later. A pancreatic islet tumor had been previously identified; however, its details were unavailable. He was presented to the emergency department 24 h after receiving the first gonadotropin-releasing hormone agonist injection. He showed severe headache, general fatigue, diplopia, and ptosis of the right eye. Brain MRI revealed a right deviated suprasellar pituitary adenoma with hemorrhagic infarction. He was conservatively treated with high-dose steroids; symptoms improved within 1 week.
[CONCLUSION] Clinicians should be aware of the association of pituitary apoplexy with the use of gonadotropin-releasing hormone agonist and should ask about the patient's past history of multiple endocrine neoplasia (MEN).
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Prostate Cancer Care for Men with an Intellectual Disability: A Population-based Cohort Study of Symptoms, Diagnosis, Treatment, and Survival.
- Association between polygenic risk scores and cardiovascular events in prostate cancer patients receiving androgen deprivation therapy in Han Chinese.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Interleukin-11: A pivotal player and potential therapeutic target in prostate cancer.
- DIAPH3 is a multifaceted prognostic biomarker that links immunotherapy response to tumor microenvironment in prostate cancer.
- Machine learning approaches to optimize the integration of sociodemographic factors for predicting cancer-specific survival among patients with high-risk prostate cancer.